CoChat
Sign Up
Cited by 116Diabetes Treatment and ManagementDiabetes Management and ResearchDiabetes, Cardiovascular Risks, and Lipoproteins

Glibenclamide vs Gliclazide in Type 2 Diabetes of the Elderly

Tessier, D., Dawson, K., Tétrault, J.P., Bravo, G., Meneilly, G.S.·1994·Diabetic Medicine
DOI 10.1111/j.1464-5491.1994.tb00256.x
Open this paper in CoChat — free account

Abstract

The objective of this study was to compare the effect of two sulphonylureas on the frequency of hypoglycaemic events and glycaemic control in elderly patients with Type 2 diabetes. Twenty‐two untreated elderly patients were treated with glibenclamide or gliclazide in a randomized double‐blind fashion. Prior to treatment, a biochemical profile, an oral glucose tolerance test, and a 2‐h hyperglycaemic glucose clamp (glucose 5.4 mmol I‐zs‐1 above baseline) were performed. Patients were seen regularly over 6 months to assess glycaemic control and the frequency of hypoglycaemic reactions. Hyperglycaemic clamp studies and oral glucose tolerance tests were repeated at 1 and 6 months. The area under the curve for the oral glucose tolerance test (glibenclamide: 15.5 ± 0.7; gliclazide: 14.9 ± 0.8 mmol I−1 ((p = NS)) and the haemoglobin A1C (glibenclamide: 7.4 ± 0.2%; gliclazide: 7.9 ± 0.5% (p = NS)) were similar at 6 months. Hypoglycaemic reactions were significantly more frequent with glibenclamide than with gliclazide: 17 vs 4 (p < 0.01). Insulin sensitivity index (ml kg−1 min−1 pmol −1 × 100) was increased significantly by glibenclamide but not gliclazide (glibenclamide: 0.284 ± 0.116 (baseline) vs 0.518 ± 0.102 (6 months) (p < 0.05), gliclazide: 0.260 ± 0.048 (baseline) vs 0.358 ± 0.048 (6 months) (p = NS)). We conclude that glycaemic control was equivalent with the two drugs but the incidence of hypoglycaemic reactions was significantly greater with glibenclamide probably because this drug increases insulin sensitivity to a greater degree.

Integrity signals

Registry

Crossref · 10.1111/j.1464-5491.1994.tb00256.x

Cites

19 of 19 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Glyburide is associated with significantly more episodes of severe hypoglycemia than gliclazide because its hypoglycemic effects last for 24 h as a consequence of the presence of active metabolites.

    “Glyburide is associated with significantly more episodes of severe hypoglycemia than gliclazide (112) because its hypoglycemic effects last for 24 h (111) as a consequence of the presence of active metabolites (111,113).”

    From Hypoglycemia in Type 2 Diabetes (2005) · cites this paper as [112]

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Related

Authors
Tessier, D., Dawson, K., Tétrault, J. P., Bravo, G., & Meneilly, G. S.
Affiliations
  • Université de Sherbrooke (CA)
  • University of British Columbia (CA)
Corresponding author
Tessier, D.
ORCID
Venue
Diabetic Medicine
Publisher
Wiley
Published
1994-12
Volume
11
Issue
10
Pages
974-980
ISSN
  • 0742-3071 (ISSN-L)
  • 1464-5491
DOI
10.1111/j.1464-5491.1994.tb00256.x
OpenAlex
W1972654341
Cited by
116
References
19
Citations by year
2023: 1 · 2022: 3 · 2021: 5 · 2020: 4 · 2019: 3 · 2018: 4 · 2017: 1 · 2016: 4 · 2015: 5 · 2014: 6 · 2013: 9 · 2012: 9
FWCI
1.76
Type
journal article
Language
en
Open access
closed
Licence
onlinelibrary.wiley.com/termsAndConditions#vor (vor, 5355 d)
Locations
  • Diabetic Medicine (publishedVersion)
  • PubMed (publishedVersion)
Funders
Servier
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
Keywords
glibenclamide, gliclazide, sulfonylureas, type 2 diabetes, elderly patients, hypoglycemia, glycemic control, insulin sensitivity, HbA1c, oral glucose tolerance test
MeSH terms
Aged, Blood Glucose, Diabetes Mellitus, Type 2, Female, Glyburide, Gliclazide, Humans, Hypoglycemia, Male

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review